Table 1.
Immunophenotype, ALK status, and basic clinical information for cases in this study
| ALK(+) ALCL (n = 33) | ALK(–) ALCL (n = 25) | AITL (n = 9) | PTCL-NOS (n = 11) | |||||
|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | |
| Age, years | ||||||||
| Median | 18 | 60 | 63 | 72 | ||||
| Range | 3-62 | 16-84 | 30-83 | 24-97 | ||||
| Male:female | 1.31 | 4.75 | 1.25 | 2.67 | ||||
| Stage | ||||||||
| I to II | 3/18 | 16.67 | 3/12 | 25 | N/A | 2/4 | 50 | |
| III to IV | 15/18 | 83.33 | 9/12 | 75 | N/A | 2/4 | 50 | |
| OS, months | ||||||||
| Median | 40.9 | 19.8 | 26.6 | 27.8 | ||||
| Range | 2-206 | 8-163.2 | 6.7-113.9 | 0.5-67.4 | ||||
| EFS, months | ||||||||
| Median | 28.7 | 10.32 | 6.9 | 6.15 | ||||
| Range | 1.1-206 | 3.2-47 | 1.1-92.4 | 0.5-34.8 | ||||
| Immunophenotype | ||||||||
| ALK | 33/33 | 100 | 0/25 | 0 | 0/3 | 0 | 0/5 | 0 |
| CD30 | 33/33 | 100 | 25/25 | 100 | 5/7 | 71.43 | 1/7 | 14.29 |
| CD3 | 5/30 | 16.67 | 14/24 | 58.33 | 9/9 | 100 | 11/11 | 100 |
| CD2 | 3/6 | 50 | 6/6 | 100 | N/A | 3/3 | 100 | |
| CD4 | 6/14 | 42.86 | 9/15 | 60 | 4/4 | 100 | 5/5 | 100 |
| CD5 | 5/13 | 38.46 | 5/11 | 45.45 | 7/7 | 100 | 9/9 | 100 |
| CD8 | 2/18 | 11.11 | 3/20 | 15 | 1/3 | 33.33 | 0/4 | 0 |
| CD43 | 6/7 | 85.71 | 4/7 | 57.14 | 5/5 | 100 | 5/5 | 100 |
| Granzyme B/perforin/TIA-1) | 14/18 | 77.78 | 10/19 | 52.63 | N/A | N/A | ||
| PAX-5 | 0/15 | 0 | 0/17 | 0 | N/A | N/A | ||
| CD20 | 0/20 | 0 | 0/13 | 0 | 1/8 | 12.5 | 0/9 | 0 |
| ALK translocation | 11/12 | 91.67 | 0/9 | 0 | N/A | 1/1 | 100 | |
| TCR rearrangement | 4/6 | 66.67 | 13/14 | 92.86 | 3/3 | 100 | 3/4 | 75 |
EFS, event-free survival; N/A, not applicable; OS, overall survival.